Ann: Anti-Calcification Study, page-59

My apologies, I didn’t mean to come across as condescending but it does frustrate me how little research some investors do, but each to their own.

The Inspiris Resilia Aortic Valve is already on the market and Resilia is the treated tissue used in that valve. Aimed at younger patients.

We have to understand that now that TAVR has been approved in younger lower risk patients there is a mad scramble for companies to market durability and anti calcification. It’s a big deal for these companies now and the perfect storm for AVR.

We have over 10 years of anti calcification data for adapt treated tissue in Paediatric patients and many studies demonstrating this.

This is a disclaimer at the bottom of the brochure advertising Resilia for younger patients and spruiking anti calcification and durability claims (my emphasis as they would not do this):

†Noclinical data are available that evaluate the long-term impact of RESILIA tissue in patients.